(Reuters) - Company officials told analysts in a conference call that the impressive overseas sales growth was due largely to "destocking" by Japanese wholesalers in the year-ago period. Lilly said it still expects sales of the drug to be flat this year. Sales have slowed amid concerns that the drug causes weight gains that could increase the risk of diabetes.
Executives of the Indianapolis-based drugmaker also said they plan later this year to ask U.S. regulators for permission to market the company's Cymbalta depression drug as a treatment for fibromyalgia, a condition involving pain in the muscles, ligaments and tendons that is often accompanied by severe fatigue.
Read more at Reuters.com Market News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment